



Curriculum Vitae

Personal information **Markus Zeitlinger**

Work experience

1. Employer: Medical University of Vienna
 - Start date: 102001
 - End date:
 - Position: Assoc. Prof.
 - Activities:
 - Country: Austria
2. Employer: Medical University of Vienna
 - Start date: 102015
 - End date:
 - Position: Head of Department
 - Activities:
 - Country: Austria

Education and training

1. Subject:
 - Start date:
 - End date:
 - Qualification: Specialist in Internal Medicine and Clinical Pharmacology
 - Organisation:
 - Country:

Additional information

Publications

20 selected publications from the last 5 years (out of overall approx. 300 peer reviewed publications): 1) Sauer mann R, Burian B, Burian A, Jäger W, Höferl M, Stella A, Theurer S, Riedl M, Zeitlinger M. Tissue pharmacokinetics of ertapenem at steady state in diabetic patients with leg infections. *J Antimicrob Chemother.* 2013 Apr;68(4):895-9. 2) Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M. Blood, tissue and intracellular concentrations of Azithromycin and after end of therapy. *Antimicrob Agents Chemother.* 2013 Apr;57(4):1736-42. 3) Wressnigg N, Pöllabauer EM, Aichinger G, Portsmouth D, Löw Baselli A, Fritsch S, Livey I, Crowe BA, Schwendinger M, Brühl P, Pilz A, Dvorak T, Singer J, Firth C, Luft B, Schmitt B, Zeitlinger M, Müller M, Kollaritsch H, Paulke Korinek M, Esen M, Kreamsner PG, Ehrlich HJ, Barrett PN. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. *Lancet Infect Dis.* 2013 Aug;13(8):680-9. 4) Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Müller M, Langer O. Using Positron Emission Tomography to Study Transporter-Mediated Drug-Drug Interactions in Tissues. *Clin Pharmacol Ther.* 2014 Aug;96(2):206-13. 5) Bauer M, Karch R, Zeitlinger M, Liu J, Koepf MJ, Asselin MC, Sisodiya SM, Hainfellner JA, Wadsak W, Mitterhauser M, Müller M, Pataraja E, Langer O. In vivo P-glycoprotein function before and after epilepsy surgery. *Neurology.* 2014 Oct 7;83(15):1326-31. 6) Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[(11)C]verapamil PET study. *J Cereb Blood Flow Metab.* 2015 May;35(5):743-6. 7) Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Müller M, Wicha WW, Strickmann DB, Prince W. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. *J Antimicrob Chemother.* 2016 Apr;71(4):1022-6. 8) Matzneller P, Lackner E, Lagler H, Wulkersdorfer B, Österreicher Z, Zeitlinger M. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. *Antimicrob Agents Chemother.* 2016 May 23;60(6):3617-25. 9) Matzneller P, Österreicher Z, Reiter B, Lackner E, Stimpfl T, Zeitlinger M. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. *J Antimicrob Chemother.* 2016 Nov;71(11):3179-3184. 10) Scarpignato C, Dolak W, Lanas A, Matzneller P, Renzulli C, Grimaldi M, Zeitlinger M, Bjarnason I. Rifaximin Reduces Number and Severity of Intestinal Lesions Associated With use of Non-steroidal Anti-inflammatory Drugs in Humans. *Gastroenterology.* 2017 Apr;152(5):980-982.e3. 11) Matzneller P, Strommer S, Drucker C, Petroczi K, Schörgenhofer C, Lackner E, Jilma B, Zeitlinger M. Colistin reduces LPS-triggered inflammation in a human sepsis model in vivo: A randomized controlled trial. *Clin Pharmacol Ther.* 2017 Jun;101(6):773-781. 12) Wulkersdorfer B, Jaros D, Eberl S, Poschner S, Jäger W, Cosentini E, Zeitlinger M, Schwameis R. Human Bile Reduces Antimicrobial Activity of Selected Antibiotics Against *Enterococcus faecalis* and *Escherichia coli* in vitro. *Antimicrob Agents Chemother.* 2017 Jul 25;61(8). 13) Schwameis R, Syré S, Marhofer D, Appelt A, Burau D, Sarahrudi K, Kloft C, Zeitlinger M. Pharmacokinetics of Cefuroxime in Synovial Fluid. *Antimicrob Agents Chemother.* 2017 Sep 22;61(10). 14) Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos E, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O. Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. 2018 Jul;104(1):139-147. 15) Schwameis R, Syré S, Sarahrudi K, Appelt A, Marhofer D, Burau D, Kloft C, Zeitlinger M. Penetration of linezolid into synovial fluid and muscle tissue after elective arthroscopy. *J Antimicrob Chemother.* 2017 Oct 1;72(10):2817-2822. 16) Hosmann A, Ritscher LC, Burgmann H, Österreicher Z, Jäger W, Poschner S, Knosp E, Reinprecht A, Gruber A, Zeitlinger M. Concentrations of cefuroxime in brain tissue of neurointensive care patients. *Antimicrob Agents Chemother.* 2018 Jan 25;62(2). 17) Zeitlinger M. Extended infusion putting the benefit into context. *Lancet Infect Dis.* 2018 Apr;18(4):380-381. 18) Österreicher Z, Lackner E, Jäger W, Höferl M, Zeitlinger M. Lack of dermal penetration of topically applied gentamicin as pharmacokinetic evidence insufficient efficacy. *J Antimicrob Chemother.* 2018 Oct 1;73(10):2823-2829. 19) Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jäger W,

Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer O. A Proof_of_Concept Study to Inhibit ABCG2_ and ABCB1_Mediated Efflux Transport at the Human Blood_Brain Barrier. J Nucl Med. 2018 Oct 1;15(10):4589_4598. 20) Oesterreicher ZA, Eberl S, Nussbaumer_Proell A, Peilensteiner T, Zeitlinger M. Impact of different pathophysiological conditions on antimicrobial activity of glycopeptides in vitro. Clin Microbiol Infect. 2019 Jun;25(6):759.e1_759.e7.

Projects

Peer reviewed grants since 2012 (total > 6.500.000 Euro): 2014_2018, Grant of the European IMI program, "New Drugs 4 Bad Bugs" (COMPACTE MAGNET) 2015_2016, Grand of the Austrian National Bank, Cerebral Microdialysis for Determination of Brain Penetration of Antibiotics 2017_2018, KLIF/FWF, Validation and Optimization of PK/PD Development Pathways of Antibiotics 2019_2023, H2020_MSCA_ITN_2019, Marie S. Curie_Actions -Training Networks for "Training towards Personalized Antibiotic Treatment" (TIPAT) 2019_2024, Grant of the European IMI2 JU AMR Accelerator program: H2020_JTI_IMI2_2018_16_01 (RespiriTB) 2019_2024, Grant of the European IMI2 JU AMR Accelerator program: H2020_JTI_IMI2_2018_16_02 (RespiriNTM) 2019_2021, Grant of the European IMI2 JU AMR Accelerator program: H2020_JTI_IMI2_2018_16_04 (AB_DiRecT) 2019_2024, Grant of the European IMI2 JU AMR Accelerator program: H2020_JTI_IMI2_2018_16_07 (GNA_NOW) 2021, VACCELERATE Grant of HORIZON 2020 - The framework program for research and development

Memberships

International Society of Anti_Infective Pharmacology (ISAP) Österreichische Pharmakologische Gesellschaft (Austrian Pharmacological Society, APHAR) Österreichische Gesellschaft für antimikrobielle Chemotherapie (ÖGACH, Austrian Society of Antimicrobial Chemotherapy) Österreichische Gesellschaft für Infektionskrankheiten (ÖGI, Austrian Society of Infectious Diseases) Paul Ehrlich Gesellschaft für Chemotherapie e.V. (PEG) European Society of Clinical Microbiology and Infectious Disease (ESCMID) ESCMID PK/PD of Anti_Infectives Study Group (EPASG) Gesellschaft für Pharmazeutische Medizin (GPMed, Society for Pharmaceutical Medicine) European Association for Clinical Pharmacology and Therapeutics (EACPT) Federation of European Pharmacological Societies (EPHAR) Österreichische Gesellschaft für Innere Medizin (ÖGIM, Austrian Society of Internal Medicine) Alumni Club Medical University of Vienna American Society for Clinical Pharmacology and Therapeutics (ASCPT) Verein zur Förderung von Wissenschaft und Forschung, General Hospital Vienna (VFWF) Österreichische Plattform für Personalisierte Medizin (ÖPPM)

Other Relevant Information

Editorial positions Scientific journals: November 2017_present Editorial Board "Pharmainformation" January 2019_present Managing Editor European Journal of Clinical Pharmacology September 2019_present Editorial Board Clinical Pharmacokinetics September 2019_present Scientific Committee of Clinical Microbiology and Infection April 2020_present Editorial Board "Microorganisms" January 2021 - present Scientific Board "Spectrum Oncology" January 2022 - present Associate Editor "Frontiers in Antibiotics" January 2023 Editor "Journal of Antimicrobial Chemotherapy" Teaching: Involvement in over 120 University lectures and courses Supervision of 14 doctoral thesis (postdoc) and 42 diploma or master thesis since 11/2009 Teacher at the Master of Public health, MUW Clinical study experience: since 2001 Conducting over 150 clinical studies including first in men studies as well as all phases of clinical drug development 11/2021 last GCP training and test